What question did this study set out to answer?

The research aims to explore how often pemphigus foliaceus is misdiagnosed as psoriasis and the consequences of this misdiagnosis.

May 9, 2026

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis

Key Points

The research aims to explore how often pemphigus foliaceus is misdiagnosed as psoriasis and the consequences of this misdiagnosis.
Conducted clinical evaluations to compare diagnostic criteria between pemphigus foliaceus and psoriasis.
Analyzed patient records for accurate reporting of diagnosis.
Investigated causes and outcomes of misdiagnosis.
Reported a significant rate of misdiagnosis, with up to 30% of pemphigus foliaceus cases initially classified as psoriasis.
Outlined potential clinical repercussions of incorrect treatment between the two conditions.

Abstract

Authors Kateryna Karpoff and Omar Alani have no conflicts of interest to declare. Dr. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Added Health, Aikium, Almirall, AltruBio Inc., Alumis, Amgen, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Moonlake, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sunpharma, Takeda, Trevi, and Verrica. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Bookmark

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis

Key Points

Abstract

Cite This Study